ARTICLE | Company News
FDA approves Xifaxan for travelers' diarrhea
May 26, 2004 7:00 AM UTC
The FDA granted marketing approval to Salix (SLXP) for its Xifaxan rifaximin to treat travelers' diarrhea caused by noninvasive strains of E. coli in patients 12 and older. SLXP expects to launch the ...